{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Trindade AJ"],"funding":["NHLBI NIH HHS","National Institutes of Health","NIH HHS"],"pagination":["e13967"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9780187"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(6)"],"pubmed_abstract":["<h4>Background</h4>Reports on outcomes following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in lung transplant recipients remain limited.<h4>Methods</h4>We performed a single-center, observational study of outcomes in lung transplant recipients diagnosed with SARS-CoV-2 between 5/1/2020 and 3/15/2022 that were followed for a median of 123 days. We analyzed changes in spirometry, acute lung allograft dysfunction (ALAD) incidence, hospitalization, mechanical ventilation needs, secondary infection, and survival.<h4>Results</h4>In our cohort of 336 patients, 103 developed coronavirus disease (COVID) (27 pre-Delta, 20 Delta, and 56 Omicron-era). Twenty-five patients (24%) required hospitalization and 10 patients ultimately died (10%). Among 85 survivors who completed ambulatory spirometry, COVID-19 did not alter change in forced expiratory volume in 1 s (FEV<sub>1</sub> ) or forced vital capacity (FVC) over time compared to the preceding 6 months. The pre-COVID FEV<sub>1</sub> change was -0.05 ml/day (IQR -0.50 to 0.60) compared to -0.20 ml/day (IQR -1.40 to 0.70) post-COVID (p = .16). The pre-COVID change in FVC was 0.20 ml/day (IQR -0.60 to 0.70) compared to 0.05 ml/day (IQR -1.00 to 1.10) post-COVID (p = .76). Although the cohort overall had stable lung function, 33 patients (39%) developed ALAD or accelerated chronic lung allograft dysfunction (FEV<sub>1</sub> decline >10% from pre-COVID baseline). Nine patients (35%) with ALAD recovered lung function. Within 3 months of acute COVID infection, 18 patients (17%) developed secondary infections, the majority being bacterial pneumonia. Finally, vaccination with at least two doses of mRNA vaccine was not associated with improved outcomes.<h4>Conclusions</h4>This study describes the natural history of SARS-CoV-2 infection in a large cohort of lung transplant recipients. Although one third of patients develop ALAD requiring augmented immunosuppression, infection with SARS-CoV-2 is not associated with worsening lung function."],"journal":["Transplant infectious disease : an official journal of the Transplantation Society"],"pubmed_title":["Clinical course of SARS-CoV-2 infection and recovery in lung transplant recipients."],"pmcid":["PMC9780187"],"funding_grant_id":["K08 HL136888","R01 HL160551","K08 HL136888"],"pubmed_authors":["Hoy H","Demarest CT","Norfolk SG","Robbins IM","Shaver CM","McPherson KA","Chapin KC","Gannon WD","Erasmus DB","Bacchetta M","Trindade AJ","Lambright ES"],"additional_accession":[]},"is_claimable":false,"name":"Clinical course of SARS-CoV-2 infection and recovery in lung transplant recipients.","description":"<h4>Background</h4>Reports on outcomes following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in lung transplant recipients remain limited.<h4>Methods</h4>We performed a single-center, observational study of outcomes in lung transplant recipients diagnosed with SARS-CoV-2 between 5/1/2020 and 3/15/2022 that were followed for a median of 123 days. We analyzed changes in spirometry, acute lung allograft dysfunction (ALAD) incidence, hospitalization, mechanical ventilation needs, secondary infection, and survival.<h4>Results</h4>In our cohort of 336 patients, 103 developed coronavirus disease (COVID) (27 pre-Delta, 20 Delta, and 56 Omicron-era). Twenty-five patients (24%) required hospitalization and 10 patients ultimately died (10%). Among 85 survivors who completed ambulatory spirometry, COVID-19 did not alter change in forced expiratory volume in 1 s (FEV<sub>1</sub> ) or forced vital capacity (FVC) over time compared to the preceding 6 months. The pre-COVID FEV<sub>1</sub> change was -0.05 ml/day (IQR -0.50 to 0.60) compared to -0.20 ml/day (IQR -1.40 to 0.70) post-COVID (p = .16). The pre-COVID change in FVC was 0.20 ml/day (IQR -0.60 to 0.70) compared to 0.05 ml/day (IQR -1.00 to 1.10) post-COVID (p = .76). Although the cohort overall had stable lung function, 33 patients (39%) developed ALAD or accelerated chronic lung allograft dysfunction (FEV<sub>1</sub> decline >10% from pre-COVID baseline). Nine patients (35%) with ALAD recovered lung function. Within 3 months of acute COVID infection, 18 patients (17%) developed secondary infections, the majority being bacterial pneumonia. Finally, vaccination with at least two doses of mRNA vaccine was not associated with improved outcomes.<h4>Conclusions</h4>This study describes the natural history of SARS-CoV-2 infection in a large cohort of lung transplant recipients. Although one third of patients develop ALAD requiring augmented immunosuppression, infection with SARS-CoV-2 is not associated with worsening lung function.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2025-04-04T09:14:40.56Z","creation":"2025-04-04T09:14:40.56Z"},"accession":"S-EPMC9780187","cross_references":{"pubmed":["36271645"],"doi":["10.1111/tid.13967"]}}